Life Sciences

  • Microbiome / Nutrition / Foodtech / Lifestyle
  • Medtech / Connected health / Digital health
  • Biotech & pharmaceuticals
  • Industrial Biotech & Cleantech
  • Animal health / Animal Feed & Nutrition

Read more

Digital Technologies

  • Fintech
  • Retailtech
  • Other digital innovative solutions
  • Hardware & telecom

Read more

Sport & Performance Capital

  • Sport-Health
  • Equipment
  • Food-Nutrition
  • IOT-Digital
  • Sports practice

Read more

Blue Economy

  • Sustainable aquaculture
  • Nutrition Cosmetics Health
  • Industrial Products & Biomaterials
  • Biopolymers and biopackaging
  • Digitalization Blue 3.0
  • Recycling, Bioremediation
  • Climate & Carbon
  • Bioenergies, hydrogen

Read more

News

  • Enterome receives U.S. FDA Orphan Drug Designation for EO2463 OncoMimics™ to treat “watch-and-wait” indolent non-Hodgkin lymphoma
    28 May 2026

    Enterome receives U.S. FDA Orphan Drug Designation for EO2463 OncoMimics™ to treat “watch-and-wait” indolent non-Hodgkin lymphoma

    Enterome SA, a clinical-stage company pioneering...

  • vorteX-io raises €8.5 million to make hydrological data a driver of national sovereignty
    27 May 2026

    vorteX-io raises €8.5 million to make hydrological data a driver of national sovereignty

    VorteX -io Raises €8.5 Million from Seventure...

  • Social AdTech firm Mediads raises €3 million to accelerate its expansion into the US
    19 May 2026

    Social AdTech firm Mediads raises €3 million to accelerate its expansion into the US

    Mediads, a pioneering social adtech company since 2022...

  • Microbiotica reports positive results for MB097 in advanced melanoma
    18 May 2026

    Microbiotica reports positive results for MB097 in advanced melanoma

    Data suggests microbiome co-therapy may help overcome...

  • Enterome presents Phase 2 indolent non-Hodgkin lymphoma data at EHA showing EO2463 induces B cell target-specific CD8 T-cell expansion correlating with clinical outcomes
    12 May 2026

    Enterome presents Phase 2 indolent non-Hodgkin lymphoma data at EHA showing EO2463 induces B cell target-specific CD8 T-cell expansion correlating with clinical outcomes

    Enterome SA, a clinical-stage company pioneering...